Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, sulfasalazine treatment resulted in cosmetically acceptable hair regrowth in 23% of patients with severe alopecia areata in whom a response could be determined.

This review summarizes the current genetic research on alopecia areata, including potential new therapeutic strategies, but reports no new clinical findings.

This study found that combining a GnRH agonist with a low-dose oral contraceptive was more effective in treating hirsutism than either agent alone and prevented hypoestrogenic side effects.

This study found that platelet-rich plasma may have a role in treating chronic alopecia areata, but more long-term follow-up studies are needed to confirm its effectiveness and success rate.

This study found distinct gene expression profiles in alopecia areata-affected skin, suggesting T-cell mediated immune responses and unique gene profiles between different stages of the disease.

This study found that irreversible and severe alopecia can occur following docetaxel or paclitaxel chemotherapy in breast cancer patients.

In this study, albendazole treatment in patients with hydatid disease was associated with decreased microsomal enzyme function and induced its own metabolism, but also showed potential hepatotoxicity and severe side effects, necessitating careful monitoring.

This study observed that N-palmitoylethanolamine (PEA) may relieve pain by enhancing de novo neurosteroid synthesis, evidenced by increased allopregnanolone levels and protein expression in pain models, dependent on PPAR-α.

This study highlights cases of alopecia areata that developed during anti-TNF-α therapy, suggesting a potential link or increased frequency, particularly among individuals with a personal or family history of autoimmune diseases.

In this study, finasteride dose-dependently inhibited stress-induced increases in allopregnanolone in rats, while enhancing 20alpha-reduction of progesterone without affecting 3alpha-dihydroprogesterone or 11-deoxycorticosterone levels.

This study found that garlic gel significantly improved the efficacy of topical betamethasone valerate in treating alopecia areata compared to placebo.

This study found that increasing dietary soy oil content reduced alopecia areata development in C3H/HeJ mice, though genistein injection showed no significant effect.

This review discusses the causes and diagnosis of traction alopecia, emphasizing education for high-risk populations as there is currently no cure, and presents no new clinical findings.

This study suggests that CD8+ cytotoxic T lymphocytes play a crucial role in the development of alopecia areata, based on observations in rodent models that mimic human autoimmune disease.

This article proposes a hypothesis for alopecia areata hair loss patterns and provides epidemiological evidence supporting distinct hair loss characteristics between general cases and those with androgenetic alopecia; it presents no new clinical results.

This study reports that intralesional triamcinolone acetonide was effective and well-tolerated for treating extensive alopecia areata in patients who often showed specific initial hair characteristics.

In this study, serum from patients with alopecia areata or universalis did not affect hair growth in transplanted scalp skin grafts on nude mice, despite increased deposition of immunoreactants.

This study found IL-17/IL-36 signaling to be predominant in both endotypes of Netherton syndrome, with distinct molecular profiles between NS-ILC and NS-SE lesions, offering potential therapeutic targets.

This study found that nanostructured lipid carriers with more soybean phosphatidylcholine provided better skin retention and follicular targeting for diphencyprone compared to other formulations and controls.

This review discusses the multiple layers of environmental controls on hair stem cell homeostasis and suggests that targeting these layers could offer safer regenerative medicine therapies without directly using stem cells.

This study reports that C3H/HeJ mice and DEBR rats serve as effective models for screening potential treatments for human alopecia areata, despite certain challenges in predictability and cost.

This study suggests the existence of a new subtype of alopecia, called 'acute diffuse and total alopecia of the female scalp (ADTAFS)', characterized by acute, diffuse hair loss primarily in women and a rapid recovery.

This review discusses the psychological impact of alopecia on women and reports no new clinical findings, highlighting the effect on self-esteem and quality of life.

This review evaluates the therapeutic potential of platelet-rich plasma for treating non-cicatricial alopecias and suggests it may be effective, though further research is needed to confirm its efficacy.

Alopecia areata severity is linked to increased TH1 and TH2 activity.

This study found that topical immunotherapy affects angiogenesis and immune cell ratios in the scalp, potentially offering insights into the mechanisms underlying alopecia areata.

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

This study found that type 2 immunity may play a role in the development of alopecia areata in patients with extrinsic atopic dermatitis, indicating different immunological states compared to non-atopic patients.

This background review discusses alopecia areata, highlighting the role of CD8+NKG2D+ T cells in hair follicle pathogenesis, and notes that the exact mechanisms causing hair loss remain unclear.